The objective of this study is to focus on drug therapy for multiple-drug resistant Pseudomonas aeruginosa. This study will identify likely sites of infection and describe the therapeutic options for this bacterium. This study will discuss the primary choice and a secondary choice for drug therapy. Finally, this study will discuss the mechanism of action and side effects of drug therapy. Pseudomonas aeruginosa is described as a “Gram-negative opportunistic nosocomial pathogen”. (Meletis and Bagkeri, 2013, p.1) This pathogen is the cause of a broad range of infections that result in antimicrobial resistance at high rates.
This microorganism’s genome is one of the world’s largest, the result is a genetic capacity that is great in nature, and as well, this pathogen has a great capacity for adaptation to changes in the environment. Common sites of infection include the urinary tract, surgical site infection, respiratory infections, and ear infections among others. Pseudomonas aeruginosa is reported as being resistant to antimicrobial agents that are most commonly used in treating infection. It is reported that two drug combinations can be used in treating this pathogen and specific medications used depend greatly upon the site of the infection. It is reported that the new carbapenems for treating this infection are those of Doripenem and biapenem. It is reported however, that the most effective medications in treating multi-drug resistant Pseudmonas aeruginosa are polymyxins.
Use your promo and get a custom paper on
"Pseudmonas Aeruginosa".
A new approach in treatment is reported and specifically those of experimental polypeptides. It is stated that the “anti-PcrV immunoglobulin G blocks the type III secretion system-mediated virulence of P. aeruginosa”. (Journal of Antimicrobial Chemotherapy, 2013, p.1) In a study that relates two treatment options with the anti-PcrV immunoglobulin G, and in which two groups of patients received two treatment options: (1) a 15 day treatment; and (2) an eight day treatment, it is reported that the side effects were that there was a higher rate of pulmonary infection reoccurring in patients who received the shorter treatment option of this treatment regimen.
